- Galeterone
- Ganetespib
- Ganitumab
- GDA-201, Nicotinamide-Expanded Allogeneic Natural Killer Cells &
- Gefitinib - IRESSA®
- Gemcitabin - GEMZAR® sowie Generika Gemcitabin Accord, -Freseniu
- Gemtuzumab Ozogamicin - MYLOTARG®
- GEN3013 (DuoBody®-CD3xCD20)
- Gilteritinib – XOSPATA (USA)
- Glasdegib – DAURISMO® (USA)
- GSK-3 Inhibitor 9-ING-41
Galeterone
According to the NCI website, Galeterone is an orally bioavailable small-molecule androgen receptor modulator and CYP17 lyase inhibitor with potential antiandrogen activity.
Ganetespib
According to the NCI website Ganetespib is a synthetic small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity.
Abstract from Molecular Cancer Therapeutics:
Targeted inhibition of the molecular chaperone heat shock protein 90 (Hsp90) results in the simultaneous blockade of multiple oncogenic signaling pathways and has thus emerged as an attractive strategy for the development of novel cancer therapeutics. Ganetespib (formerly known as STA-9090) is a unique resorcinolic triazolone inhibitor of Hsp90 currently in clinical trials for a number of human cancers. Here we show that ganetespib exhibits potent in vitro cytotoxicity in a range of solid and hematological tumor cell lines, including those that express mutated kinases that confer resistance to small molecule tyrosine kinase inhibitors (TKIs). Ganetespib treatment rapidly induced the degradation of known Hsp90 client proteins, displayed superior potency to the ansamycin inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG), and exhibited sustained activity even with short exposure times. In vivo, ganetespib demonstrated potent antitumor efficacy in solid and hematological xenograft models of oncogene addiction, as evidenced by significant growth inhibition and/or regressions. Of note, evaluation of the microregional activity of ganetespib in tumor xenografts showed that ganetespib efficiently distributed throughout tumor tissue, including hypoxic regions >150 μm from the microvasculature, to inhibit proliferation and induce apoptosis. Importantly, ganetespib showed no evidence of cardiac or liver toxicity. Taken together, this preclinical activity profile suggests that ganetespib may have broad application for a variety of human malignancies, and with select mechanistic and safety advantages over other first- and second-generation Hsp90 inhibitors. Molecular Cancer Therapeutics
Link to National Cancer Institute
Ganitumab
According to the NCI website, ganitumab is a recombinant, fully human monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity.
Link to Drug Information Portal, a service of the U.S. National Library of Medicine, National Institutes of Health
Link to National Cancer Institute
Link zu Wiki
GDA-201, Nicotinamide-Expanded Allogeneic Natural Killer Cells (NAM-NK)
Alternative Names according to Adis Insight: GDA-201; NAM NK cells - Gamida; NAM-NK Cells; Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
Published: Mar 02, 2020
Gefitinib - IRESSA®
Gefitinib - IRESSA® ist ein Anilinochinazolin mit antineoplastischer Aktivität. Gefitinib hemmt die katalytische Aktivität zahlreicher Tyrosinkinasen einschließlich des epidermalen Wachstumsfaktorrezeptors (EGFR), was zur Hemmung des Tyrosinkinase-abhängigen Tumorwachstums führen kann. Insbesondere konkurriert Gefitinib mit der Bindung von ATP an die Tyrosin-Kinase-Domäne von EGFR um damit die Rezeptor-Autophosphorylierung zu hemmen und letztlich die Hemmung der Signalübertragung. Gefitinib kann auch den Stillstand des Zellzyklus induzieren und die Angiogenese hemmen.
Indikationen/Anwendungsmöglichkeiten gemäss Arzneimittel-Kompendium der Schweiz®:
- IRESSA ist indiziert zur Behandlung von Patienten mit Adenokarzinom der Lunge und aktivierender EGFR Mutation, wenn eine platinhaltige Chemotherapie versagt hat oder nicht möglich ist.
More Information in English:
Link to National Cancer Institute
Link zu Wiki
Link zu PharmaWiki
Link to European Medicines Agency (EMEA)Link to Physicians Desk Reference (PDR)
Info for Patients presented by Scott Hamilton from Chemocare.com
Introduction to Small Molecule Tyrosine Kinase Inhibitors presented by OncoLink
Gemcitabin - GEMZAR® sowie Generika Gemcitabin Accord, -Fresenius, -Labatec, -Sandoz, -Teva
The hydrochloride salt of an analogue of the antimetabolite nucleoside deoxycytidine with antineoplastic activity.
Indikationen/Anwendungsmöglichkeiten gemäss Compendium®:
Gemzar® ist laut Compendium® indiziert
- zur palliativen Behandlung von Patienten mit fortgeschrittenem oder metastasierendem nicht- kleinzelligem Lungenkarzinom.
- zur Behandlung von Patienten mit lokal fortgeschrittenem (Stadium II oder III) oder metastasierendem Pankreas-Adenokarzinom. Dies gilt auch für mit 5-FU vorbehandelte Patienten.
- zur Behandlung bei inoperablem, lokal fortgeschrittenem oder metastasierendem Blasenkarzinom in Kombination mit Cisplatin.
- in Kombination mit Carboplatin zur Behandlung von Patientinnen mit rezidivierendem Ovarialkarzinom nach einer mindestens 6 Monate zurückliegenden platinhaltigen Therapie.
- in Kombination mit Paclitaxel zur Behandlung von Patientinnen mit nicht operablem, lokal wiederauftretendem oder metastasierendem Mammakarzinom, bei denen es nach einer adjuvanten/neoadjuvanten Chemotherapie zu einem Rezidiv kam. Die vorausgegangene Chemotherapie sollte ein Anthracyclin enthalten haben, sofern dieses nicht klinisch kontraindiziert war.
Link to Drug Information Portal, a service of the U.S. National Library of Medicine, National Institutes of Health
Link to MedlinePlus, a service of the U.S. National Library of Medicine, National Institutes of Health
Link to National Cancer Institute
Link zu Wiki
Link zu PharmaWiki
Link to Physicians Desk Reference (PDR)
Link to European Medicines Agency (EMEA)
Link zur Fachinformation des Compendium®
Info for Patients presented by Scott Hamilton from Chemocare.com
Gemtuzumab Ozogamicin - MYLOTARG®
According to the NCI, gemtuzumab ozogamicin is a recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin.
Indikationen/Anwendungsmöglichkeiten gemäss Chemocare.com:
Gemtuzumab ozogamicin is used to treat patients with CD33 positive acute myeloid leukemia (AML) in first relapse who are 60 years of age or older and for whom other chemotherapy is not recommenced.
Note: If a drug has been approved for one use, physicians may elect to use this same drug for other problems if they believe it may be helpful.
- Mylotarg wird angewendet für die Kombinationstherapie mit Daunorubicin (DNR) und Cytarabin (AraC) zur Behandlung von erwachsenen Patienten mit nicht vorbehandelter, neu diagnostizierter CD33‑positiver akuter myeloischer Leukämie (AML), ausgenommen akuter Promyelozytenleukämie (APL) (siehe «Warnhinweise und Vorsichtsmassnahmen» und «Klinische Wirksamkeit»).
Fachinformationen gemäss Compendium®
Link to MedlinePlus, a service of the U.S. National Library of Medicine, National Institutes of Health
Link to National Cancer Institute
Link zu Wiki
Link zu PharmaWiki
Link to Physicians Desk Reference (PDR)
Link to European Medicines Agency (EMEA)
Info for Patients presented by Scott Hamilton from Chemocare.com
Monoclonal antibodies for tumors
GEN3013 (DuoBody®-CD3xCD20)
According to the NCI website, the anti-CD3/CD20 bispecific antibody GEN3013 is a bispecific monoclonal antibody, with potential immunomodulating and antineoplastic activities. Check for active clinical trials using this agent.
Link to National Cancer Institute
Bispecific monoclonal antibody
Gilteritinib – XOSPATA (USA)
According to the NCI website, Gilteritinib is an orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-related tyrosine kinase 3, AXL and anaplastic lymphoma kinase, with potential antineoplastic activity. Check for active clinical trials using this agent.
Indikationen/Anwendungsmöglichkeiten gemäss Compendium.ch®
- Behandlung von erwachsenen Patienten, die an rezidivierter oder refraktärer akuter myeloider Leukämie (AML) mit FMS-ähnlichen Tyrosinkinase 3 (FLT3)-Mutationen leiden (siehe «Klinische Wirksamkeit»).
More Information in English:
Link to MedlinePlus, a service of the U.S. National Library of Medicine, National Institutes of Health
Link to National Cancer Institute
Link zu PharmaWiki
Link to Physicians Desk Reference (PDR)
Link to European Medicines Agency (EMEA)
Info for Patients presented by Scott Hamilton from Chemocare.com
Glasdegib – DAURISMO® (USA)
According to the NCI website, glasdegib maleate is the salt form of glasdegib, an orally bioavailable small-molecule, smoothened (SMO) receptor inhibitor, with potential antineoplastic activity. Check for active clinical trials using this agent.
More Information in English:
Link to MedlinePlus, a service of the U.S. National Library of Medicine, National Institutes of Health
Link to National Cancer Institute
Link zu PharmaWiki
Link to Physicians Desk Reference (PDR)
Link to European Medicines Agency (EMEA)
Info for Patients presented by Scott Hamilton from Chemocare.com
GSK-3 Inhibitor 9-ING-41
According to the NCI website, 9-ING-41 is a maleimide-based, small molecule inhibitor of glycogen synthase kinase-3 (GSK-3; serine/threonine-protein kinase GSK3) with potential antineoplastic activity. Check for active clinical trials using this agent. (NCI Thesaurus)
More Information in English:
Link to Drug Information Portal, a service of the U.S. National Library of Medicine, National Institutes of Health
Link to National Cancer Institute